SAMe-1,4-Butanedisulfonate 

SAMe-1,4-Butanedisulfonate, a natural compound, is a methyl donor in the central nervous system. SAMe-1,4-Butanedisulfonate has antidepressant activity. SAMe-1,4-Butanedisulfonate can be used for research of CNS disorders^[1][2][3][4].

SAMe-1,4-Butanedisulfonate (30 and 60 mg/kg/day, i.m) increases the thickness and cell density of lesioned cartilages in experimental osteoarthritis rabbit^[2].
SAMe-1,4-Butanedisulfonate (60 and 100 mg/kg/day, i.m) protects from liver injury induced by d-galactosamine in rats^[3].
SAMe-1,4-Butanedisulfonate (10-200 mg/kg, i.p.) shows antidepressant-like effects mice submitted to the forced swimming test (FST) and tail suspension test (TST)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

726.82

C₁₅H₂₃N₆O₅S.C₄H₁₀O₆S₂.1/2C₄H₈O₆S₂

101020-79-5

O=S(CCCCS(=O)(O)=O)(O)=O.NC1=NC=NC2=C1N=CN2[C@H]3[C@H](O)[C@H](O)[C@@H](C[S+](CC[C@H](N)C(O)=O)C)O3.O=S(CCCCS(=O)([O-])=O)([O-])=O.[1/2]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Delle Chiaie R, et al. Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. Am J Clin Nutr. 2002 Nov;76(5):1172S-6S.  [Content Brief]

  [2]. Barceló HA, et al. Osteoartritis experimental y su evolución bajo tratamiento con S-adenosil-L-metionina (SAMe) [Experimental osteoarthritis and its course when treated with S-adenosyl-L-methionine]. Rev Clin Esp. 1990 Jun;187(2):74-8. Spanish.  [Content Brief]

  [3]. Stramentinoli G, et al. Protective role of S-adenosyl-L-methionine on liver injury induced by D-galactosamine in rats. Biochem Pharmacol. 1978 May 15;27(10):1431-3.  [Content Brief]

  [4]. Sales AJ, et al. S-adenosyl-l-methionine antidepressant-like effects involve activation of 5-HT1A receptors. Neurochem Int. 2023 Jan;162:105442.  [Content Brief]